Private Management Group Inc. cut its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 6.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,375,431 shares of the company’s stock after selling 92,921 shares during the period. Private Management Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $22,351,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. Maple Rock Capital Partners Inc. lifted its position in Teva Pharmaceutical Industries by 68.3% during the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock worth $61,568,000 after buying an additional 1,770,000 shares in the last quarter. Glenview Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth $16,752,000. Iron Triangle Partners LP boosted its position in shares of Teva Pharmaceutical Industries by 113.1% during the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares during the last quarter. Norges Bank purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $14,376,000. Finally, Hsbc Holdings PLC increased its position in Teva Pharmaceutical Industries by 242.6% during the fourth quarter. Hsbc Holdings PLC now owns 1,597,178 shares of the company’s stock worth $16,667,000 after purchasing an additional 1,130,969 shares during the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, Director Roberto Mignone sold 519,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the sale, the director now directly owns 981,000 shares in the company, valued at $16,706,430. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the completion of the transaction, the director now owns 981,000 shares in the company, valued at approximately $16,706,430. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric A. Hughes sold 24,537 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total transaction of $423,263.25. Following the completion of the sale, the insider now directly owns 45,060 shares in the company, valued at $777,285. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Research Report on TEVA
Teva Pharmaceutical Industries Trading Down 1.9 %
NYSE TEVA opened at $18.08 on Monday. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89. The firm has a market cap of $20.48 billion, a price-to-earnings ratio of -44.10, a PEG ratio of 1.25 and a beta of 0.88. The firm has a 50 day simple moving average of $17.42 and a 200-day simple moving average of $15.76. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $19.08.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.35 EPS for the current fiscal year.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- How to Calculate Stock Profit
- Intel Eyes Foundry Sale: Is This the Solution to Its Stock Woes?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Best AI ETFs for Investors: Balancing Performance, Fees, and Risk
- CD Calculator: Certificate of Deposit Calculator
- Natural Gas Will Boom in 2025, and Kinder Morgan Is The Play
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.